X0202 SCHEDULE 13G 0001440771 XXXXXXXX LIVE Common Stock 05/04/2026 0001279704 Cellectar Biosciences, Inc. 15117F880 100 Campus Drive Florham Park NJ 07932 Rule 13d-1(c) Stonepine Capital Management, LLC b DE 0.00 863277.00 0.00 863277.00 863277.00 N 9.9 IA OO The securities beneficially owned by the reporting persons consist of (1) 196,930 shares of Common Stock, and (2) prefunded warrants to acquire 912,075 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 7,975,069 shares of Common Stock outstanding as of May 4, 2026, consisting of 5,858,182 shares of Common Stock outstanding following the closing of the registered offering of the Issuer's shares on May 4, 2026, and 2,116,887 shares of Common Stock issued by the Issuer in a private placement on May 4, 2026, as reported in the Form 8-K filed by the Issuer on May 8, 2026. Stonepine Capital, L.P. b DE 0.00 863277.00 0.00 863277.00 863277.00 N 9.9 PN The securities beneficially owned by the reporting persons consist of (1) 196,930 shares of Common Stock, and (2) prefunded warrants to acquire 912,075 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 7,975,069 shares of Common Stock outstanding as of May 4, 2026, consisting of 5,858,182 shares of Common Stock outstanding following the closing of the registered offering of the Issuer's shares on May 4, 2026, and 2,116,887 shares of Common Stock issued by the Issuer in a private placement on May 4, 2026, as reported in the Form 8-K filed by the Issuer on May 8, 2026. Stonepine GP, LLC b DE 0.00 863277.00 0.00 863277.00 863277.00 N 9.9 OO The securities beneficially owned by the reporting persons consist of (1) 196,930 shares of Common Stock, and (2) prefunded warrants to acquire 912,075 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 7,975,069 shares of Common Stock outstanding as of May 4, 2026, consisting of 5,858,182 shares of Common Stock outstanding following the closing of the registered offering of the Issuer's shares on May 4, 2026, and 2,116,887 shares of Common Stock issued by the Issuer in a private placement on May 4, 2026, as reported in the Form 8-K filed by the Issuer on May 8, 2026. Jon M. Plexico b X1 0.00 863277.00 0.00 863277.00 863277.00 N 9.9 HC IN The securities beneficially owned by the reporting persons consist of (1) 196,930 shares of Common Stock, and (2) prefunded warrants to acquire 912,075 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 7,975,069 shares of Common Stock outstanding as of May 4, 2026, consisting of 5,858,182 shares of Common Stock outstanding following the closing of the registered offering of the Issuer's shares on May 4, 2026, and 2,116,887 shares of Common Stock issued by the Issuer in a private placement on May 4, 2026, as reported in the Form 8-K filed by the Issuer on May 8, 2026. Cellectar Biosciences, Inc. 100 Campus Drive, Florham Park, NJ 07932 Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Ordinary Shares except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Ordinary Shares covered by this Schedule 13G. 2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703 See Item 4 of the cover sheet for each reporting person. Y Stonepine: 863,277 Partnership: 863,277 General Partner: 863,277 Jon M. Plexico: 863,277 Stonepine: 9.9% Partnership: 9.9% General Partner: 9.9% Jon M. Plexico: 9.9% Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 863,277 Partnership: 863,277 General Partner: 863,277 Jon M. Plexico: 863,277 Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 863,277 Partnership: 863,277 General Partner: 863,277 Jon M. Plexico: 863,277 Y N The Partnership holds shares for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G Stonepine Capital Management, LLC /s/ Jon M. Plexico 05/11/2026 Stonepine Capital, L.P. /s/ Jon M. Plexico 05/11/2026 Stonepine GP, LLC /s/ Jon M. Plexico 05/11/2026 Jon M. Plexico /s/ Jon M. Plexico 05/11/2026